Cover Image

Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England

Abstract Background and Objective The tyrosine kinase inhibitors cabozantinib and axitinib have been widely used in England to treat advanced renal cell carcinoma following prior vascular endothelial growth factor-targeted therapy, but data on real-world usage remain limited. Our objective was to de...

Full description

Saved in:

Bibliographic Details
Main Authors:	Janet Brown (Author), Brooke Harrow (Author), Anne Marciniak (Author), Christine McCarthy (Author), Aude Houchard (Author), Lori Cirneanu (Author), Andrew Protheroe (Author)
Format:	Book
Published:	Adis, Springer Healthcare, 2024-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England
by: Meng J, et al.
Published: (2018)

Targeted treatments in advanced renal cell carcinoma: focus on axitinib
by: Verzoni E, et al.
Published: (2014)

Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy
by: Bellesoeur A, et al.
Published: (2017)

A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
by: Tiako Meyo M, et al.
Published: (2022)

Anti-angiogenic and antioxidant effects of axitinib in human retinal endothelial cells: implications in diabetic retinopathy
by: Francesca Lazzara, et al.
Published: (2024)

Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma
by: Emeline Colomba, et al.
Published: (2022)

An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives
by: Iaxx R, et al.
Published: (2022)

Inhibition of Axitinib on Buspirone Metabolism in vitro and in vivo
by: Zhang BW, et al.
Published: (2022)

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
by: Grassi P, et al.
Published: (2016)

Cabozantinib-associated acquired perforating dermatosis
by: Denis Smirnov, MD, PhD, et al.
Published: (2024)

Variables Affecting the Preparation and Characterization of Axitinib as Oral Niosmoes
by: Ibtihal Abdulkadhim Dakhil, et al.
Published: (2024)

Axitinib after Sunitinib in metastatic renal cancer: preliminary results from Italian "Real-Word" SAX study
by: Carmine D'Aniello, et al.
Published: (2016)

Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
by: Hao Wang, et al.
Published: (2022)

HPLC method development and validation for the estimation of axitinibe in rabbit plasma
by: Achanta Suneetha, et al.
Published: (2017)

A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
by: Peiyao Lu, et al.
Published: (2020)

Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis
by: Jingyang Su, et al.
Published: (2024)

Method development and validation of cabozantinib by LC-MS/MS
by: Punna Venkateshwarlu, et al.
Published: (2022)

Cabozantinib for progressive metastatic medullary thyroid cancer: a review
by: Colombo JR, et al.
Published: (2014)

Combination of axitinib and dasatinib for anti-cancer activities in two prostate cancer cell lines
by: Nai-Xiong Peng, et al.
Published: (2015)

Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States
by: SiNi Li, et al.
Published: (2021)

Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
by: Bo Shi, et al.
Published: (2022)

Impact of Cabozantinib Exposure on Proteinuria and Muscle Toxicity in Patients with Unresectable Hepatocellular Carcinoma
by: Hironao Okubo, et al.
Published: (2022)

Brugia malayi microfilariae adhere to human vascular endothelial cells in a C3-dependent manner.
by: Jan-Hendrik Schroeder, et al.
Published: (2017)

Case report: Robust response of metastatic clear cell sarcoma treated with cabozantinib and immunotherapy
by: Rakefet Sidlik Muskatel, et al.
Published: (2022)

Design, Synthesis and In Vitro Investigation of Cabozantinib-Based PROTACs to Target c-Met Kinase
by: Anastasia A. Sachkova, et al.
Published: (2022)

Real-world experience of cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or immune checkpoint inhibitors
by: Darren MC Poon, et al.
Published: (2023)

Anti-tumor activity of cabozantinib by FAK down-regulation in human oral squamous cell carcinoma
by: Da-Lu Li, et al.
Published: (2015)

Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis
by: Hiroaki Kanzaki, et al.
Published: (2023)

Experimental models for vascular endothelial dysfunction
by: Anchal Garg, et al.
Published: (2021)

Morphology regulation in vascular endothelial cells
by: Kiyomi Tsuji-Tamura, et al.
Published: (2018)

A sensitive bioanalytical method development and validation of cabozantinib in human plasma by LC-ESI-MS/MS
by: Srikanth Inturi, et al.
Published: (2018)

Intralesional Axitinib Injection Mitigates Hypertrophic Scar by Inhibiting Angiogenesis Pathway: A Preliminary Study in a Rabbit Ear Model
by: Liu C, et al.
Published: (2023)

Vascular Abnormalities and the Role of Vascular Endothelial Growth Factor in the Epileptic Brain
by: Ari Ogaki, et al.
Published: (2020)

AKT/PACS2 Participates in Renal Vascular Hyperpermeability by Regulating Endothelial Fatty Acid Oxidation in Diabetic Mice
by: Zhihao Shu, et al.
Published: (2022)

Case Report: Clinical complete response of advanced renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion by treated by camrelizumab and axitinib: A rare case report
by: Juping Zhao, et al.
Published: (2022)

A high throughput method for Monitoring of Sorafenib, regorafenib, cabozantinib and their metabolites with UPLC-MS/MS in rat plasma
by: Er-Min Gu, et al.
Published: (2022)

Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug-Drug Interaction with Rifampin and Liver Impairment
by: Bettina Gerner, et al.
Published: (2021)

Silent hyperlipidaemia modulated vascular endothelial markers
by: Marwan Merkhan, et al.
Published: (2021)

Endothelial Progenitors as Tools to Study Vascular Disease
by: Reinhold J. Medina, et al.
Published: (2012)

Expression of BMP-2 in Vascular Endothelial Cells of Recipient May Predict Delayed Graft Function After Renal Transplantation
by: Nikolina Basic-Jukic, et al.
Published: (2016)